Unique ID issued by UMIN | UMIN000015249 |
---|---|
Receipt number | R000017733 |
Scientific Title | The development of treatment using the connectivity neurofeedback for patients with affective disorders |
Date of disclosure of the study information | 2014/09/25 |
Last modified on | 2024/04/04 19:55:51 |
The development of treatment using the connectivity neurofeedback for patients with affective disorders
The development of treatment using the connectivity neurofeedback for patients with affective disorders
The development of treatment using the connectivity neurofeedback for patients with affective disorders
The development of treatment using the connectivity neurofeedback for patients with affective disorders
Japan |
Major depressive disorder (monopolar depression) and bipolar disorder(bipolar I disorder and bipolar II disorder)
Psychiatry |
Others
NO
A main purpose of this clinical trial is to evaluate safety and efficacy, including antidepressant effect and prefrontal cognitive enhancement, of fMRI neurofeedback applied to major depressive episode.
Safety,Efficacy
Exploratory
Explanatory
1) Hamilton Depression Rating Scale (Ham-D) 17items and 24items
2) Beck Depression Inventry II (BDI-II)
3) Self-rating Depression Scale (SDS)
Interventional
Cross-over
Randomized
Cluster
Double blind -all involved are blinded
Placebo
2
Treatment
Device,equipment | Behavior,custom |
fMRI neurofeedback
Connectivity-based neurofeedback using a 3T fMRI apparatus
Duration of intervention: 1 week to 2 weeks
Dose of intervention: 6 to 10 sessions per day
20 | years-old | <= |
65 | years-old | > |
Male and Female
1. DSM-IV-TR diagnosis of major depressive disorder or bipolar disorder(BPI or II)
2. Current diagnosis of major depressive episode
3. Normal visual acuity
4. Aged 20-65 years-old, outpatients, self-sustained ADL
5. Capability of informed consent
1. Implanted cardiac pacemaker
2. Surgical aneurysm clips
3. Neurostimulator
4. Implanted pumps
5. Metal fragments in body/eyes
6. Tattoos or permanent eyeliner (if ink contains metallic specks)
7. Treatment history of ECT
8. Diagnosis of neurological disorders (including epilepsy), substance dependence, or
significant cardiac disease
9. History of neurological disorders (including epilepsy), substance dependence, or head injury with loss of consciousness
30
1st name | Jun |
Middle name | |
Last name | Miyata |
Kyoto University Graduate School of Medicine
Department of Psychiatry
606-8507
54 Shogoin-Kawara-cho Sakyo-ku Kyoto
075-751-3386
miyata10@kuhp.kyoto-u.ac.jp
1st name | Jun |
Middle name | |
Last name | Miyata |
Kyoto University Graduate School of Medicine
Department of Psychiatry
606-8507
54 Shogoin-Kawara-cho Sakyo-ku Kyoto
075-751-3386
miyata10@kuhp.kyoto-u.ac.jp
Kyoto University
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Japan
Advanced Telecommunications Research Institute International(ATR)
Kyoto University Graduate School and Faculty of Medicine, Ethics Committee
53, Kawaramachi-shogoin, Sakyo-ku, Kyoto 606-8507, Japan
075-753-4680
ethcomkuhp@kyoto-u.ac.jp
NO
2014 | Year | 09 | Month | 25 | Day |
Published
36
Main results already published
2014 | Year | 09 | Month | 19 | Day |
2014 | Year | 09 | Month | 19 | Day |
2015 | Year | 04 | Month | 01 | Day |
2024 | Year | 03 | Month | 31 | Day |
2024 | Year | 03 | Month | 31 | Day |
2024 | Year | 03 | Month | 31 | Day |
2014 | Year | 09 | Month | 25 | Day |
2024 | Year | 04 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017733